Aquestive Therapeutics, Inc. (NASDAQ:AQST) Overview and Financial Insights

Company Overview - Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a pharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs, specializing in oral film-based drug delivery systems [2][4] - Competitors include Teva Pharmaceuticals and Viatris, which also focus on drug delivery technologies [2] Recent Developments - New Street set a price target of $12 for AQST, indicating a potential upside of approximately 193% from its trading price of $4.10 [3] - Despite receiving a Complete Response Letter (CRL) from the FDA for Anaphylm, AQST's stock has increased by 38.98%, rising by $1.15 [3][4] - The CRL highlighted deficiencies in the human factors validation study, temporarily halting discussions on labeling and post-marketing commitments [4] - AQST's stock has shown volatility, with a daily trading range between $3.79 and $4.39, and has fluctuated between a high of $7.55 and a low of $2.12 over the past year [4] Market Position - AQST's market capitalization stands at approximately $500.21 million, with a trading volume of 60.81 million shares on the NASDAQ exchange [4] - The outcome of discussions to address the FDA's concerns regarding Anaphylm is crucial for the company's future, as it represents a significant opportunity in the treatment of anaphylaxis [5]